Pharmaceuticals: Dicerna | Stock Price Today

Dicerna Pharmaceuticals Inc. [NASDAQ: DRNA] Stock Overview

Dicerna Pharmaceuticals Inc. stock closed at $37.92 with a trading volume of 7,906,174 shares. The company announced on November 22, 2021, that it is being investigated for its acquisition by Novo Nordisk. Shareholders will receive $38.25 per share they own.

Analyst Insights and Market Predictions

Wall Street experts have set a target price for DRNA at $34.96 per share, with a current recommendation of 2.20, indicating a Buy rating on a scale from 1 (Strong Buy) to 5 (Strong Sell).

Goldman Sachs maintains a Neutral stance on DRNA stock, while other firms have set price targets ranging from $32 to $38. The Average True Range (ATR) for DRNA is 1.75, and the Price-to-Sales ratio stands at 15.35 for the past year.

DRNA Stock Trading Performance

Over the past few months, DRNA has shown a 24.90% gain. In the last four weeks alone, shares have surged by 73.71%, with a total 66.10% rise over the past year. The stock has been highly active, with a daily trading volume of 7.9M shares, compared to its average of 1.39M shares.

Technical Analysis: RSI and Moving Averages

The Relative Strength Index (RSI) for DRNA currently sits at 88.55, indicating overbought conditions. The stock's 50-day moving average is $22.03, and the 200-day moving average is $27.44, suggesting bullish momentum in recent weeks.

Financial Performance Overview

Dicerna Pharmaceuticals reported a net margin of 68.62% and a Return on Invested Capital (ROIC) of 62.84. The company also has a Return on Equity (ROE) of 77.77%, and a Price-to-Free-Cash-Flow ratio of 344.41.

The company's Quick Ratio is 2.50, reflecting its ability to cover short-term obligations with its most liquid assets.

Earnings Per Share (EPS) Analysis

For the latest quarter, Dicerna Pharmaceuticals reported earnings of $0.49 per share, exceeding analysts' expectations of $0.03 per share, resulting in a surprise factor of 1,533.30%.

Institutional and Insider Ownership

Approximately 83.30% of DRNA stock is held by institutional investors. Major institutional holders include RTW Investments, BlackRock Inc., and State Street Corp. Institutional positions in DRNA increased in November, with 93 institutional investors adding 13.7M shares, while 112 investors reduced their holdings by 11.4M shares.